EGF and prostate carcinoma: A new platform of NIR reagents based on IRDye 800CW was developed and used for preparation of IRDye 800CW conjugated EGF [27], [28], [34] which was accepted by NIH database as a molecular imaging and contrast agent for optical visualization of prostate carcinomas in vitro and in mice.